Herombopag for low platelets from T-DM1 in breast cancer
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests if herombopag can help raise platelet counts in breast cancer patients who have low platelets caused by the drug T-DM1 after prior anti-HER2 therapy. If it works, it may allow you to continue T-DM1 without delays or dose reductions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have breast cancer that was treated with anti-HER2 therapy before surgery and then with T-DM1 after surgery.
- You had low platelets (grade 2 or higher) from T-DM1 in your last treatment cycle, and your platelets have recovered to between 100 and 200 before the next dose.
- You are able to do daily activities with some help (ECOG score 0-2).
- You plan to receive at least two more cycles of T-DM1 at the same dose as your last cycle.
- You do not have other cancers in the last 3 years, blood disorders, recent blood clots, or severe bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug hetrombopag can safely raise platelet counts in people with immune thrombocytopenia (ITP) before they have surgery. The goal is to reduce bleeding risk during and after the operation.
This trial tests if a drug called herombopag can help prevent low platelet counts, a common side effect of the chemotherapy T-DM1. If you have HER2-positive breast cancer and are about to start T-DM1 treatment, this study may be an option for you.
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
This trial tests a drug called hetrombopag to see if it can prevent low platelet counts caused by antibody-drug conjugate (ADC) chemotherapy in breast cancer patients. It may help you avoid treatment delays or dose reductions.
This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.
This trial tests a medication called Herombopag to raise platelet counts in adults aged 60 or older with immune thrombocytopenia (ITP). The goal is to see if it is safe and effective for this age group.
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.